Compare BioNTech SE - ADR (BNTX) vs iShares China Large-Cap ETF (FXI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs iShares China Large-Cap ETF — how do they compare? BioNTech SE - ADR trades at $89.8 (market cap $22.86B), while iShares China Large-Cap ETF trades at $34.34. The key difference: iShares China Large-Cap ETF is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | FXI | |
|---|---|---|
Market Cap | $22.86B | — |
Sector | Health | — |
52-Week High | $119.34 | $41.75 |
52-Week Low | $83.89 | $31.59 |
Enterprise Value | $6.53B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
FXI trades at $33.44, down slightly (-0.12%) on the day, with technical indicators showing mixed signals between bullish moving averages and neutral oscillators. The ETF benefits from China's aggressive AI and EV investments, including a $295 billion AI infrastructure plan and 30% NEV fleet target by 2030. Recent manufacturing rebounds and strong export data provide fundamental support, though geopolitical tensions with the US pose headwinds.
Outlook remains cautiously optimistic given China's tech investment surge and manufacturing recovery. Key opportunities include exposure to AI hardware exports and domestic EV growth, while risks center on US-China trade restrictions and potential valuation pressures. The ETF offers diversified China large-cap access but requires monitoring of geopolitical developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →
